Non -invasive method allows you to evaluate pulmonary inflammation quickly. They will be daily measurements, with a simple and intuitive process.
As respiratory diseases Chronicles affect more than 400 million people worldwide and are a major cause of disability and death.
Now an Iberian team of scientists, which includes the University of Coimbra (UC) is developing a pioneer device to predict e reduce the respiratory crises of people with asma and other chronic obstructive diseases.
The tool will be for homein order to help patients and doctors anticipate and prevent respiratory crises, reducing, So, the hospitalizations and improving the quality of life.
The new device, which is being developed with the help of the artificial intelligence, allows to measure the exhaled fraction of nitric oxide (hay) at home, a noninvasive method that allows to evaluate pulmonary inflammation quickly.
So far, this monitoring is done mainly in a hospital or a clinic.
With this mobile tool, it will be possible for patients to monitor their hay levels at home, ensuring timely interventions and more effective disease management, ”explains the UC investigation team in a statement sent to ZAP.
To do this monitoring, patients must “use the device to perform daily measurements, following a simple and intuitive process. ”
The measurement is then rautomatically evasted in the mobile application of the systemwhich will store the data and allow standards to analyze over time.
Researchers believe that these data, combined with other clinical variables, may contribute significantly to the Crisis’ timely management and prevention.
Predictive models are being used that allow “analyzing hay measurements standards, crossing them with other clinical and environmental data,” explains the research team.
“We believe that this device for home use can positively impact the daily lives of people diagnosed with asthma and other pulmonary obstructive diseases, and may come to reduce up to 55% Its respiratory crises, thus preventing more than 1.2 million annual hospitalizations in Europe and releasing about 8 million days of hospital occupation, ”says the Iberian consortium team.
The University of Coimbra and the Local Health Unit of Coimbra (ULS Coimbra) are implementing a multicenter clinical study involving Portugal and Spain (Clinic Hospital of Barcelona), to evaluate the performance of the home version of the Evernoa device in patients with severe asthma.
During this study, researchers will accompany participants throughout six months, collecting data on the use of the device and the evolution of its clinical condition.
Thus, the study will allow “analyzing patient adhesion to technology, evaluating the feasibility of regular device use and understanding how this innovative methodology can impact Asthma management on real life”, contextualizes the Portuguese team.
